Sunnyvale, Calif. – August 17, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received the prestigious ‘Innovator of the Year’ for 2015 at the annual conference of EK-UNICO in Germany. With a presence in more than 20 countries, Elixir Medical was selected for this honor by the 12 German University Hospitals that make up the EK-UNICO purchasing pool headquartered in Münster.
EK-UNICO CEO, Dr. Frank Obbelode, awarded the coveted prize to Elixir Medical, a 10 year old American company, in the presence of around 120 purchasers from the 12 associated member institutions. On behalf of these associated member institutions, Dr. Frank Obbelode also thanked the representatives of Elixir Medical for their successful and faithful collaboration.
“We hope in this way to clearly express our recognition of a company that has, at its young age, proven able to combine excellence in medical technology and innovative skill with entrepreneurial success, thus making a significant contribution to improving health care for heart patients,” said Dr. Obbelode in his address. “Elixir Medical’s example clearly shows how important advances in the research and development. This is where scientific pioneering spirit, entrepreneurial initiative, and marketing skill come together – to the benefit of all the EK-UNICO-associated university hospitals and their patients.”
“Elixir Medical is honored and excited to receive this prestigious Innovator of the Year award for 2015,” said Motasim Sirhan, CEO of Elixir Medical. “We are committed to presenting innovative and state-of-the-art products to our customers, and providing them with excellent service as well.”
ABOUT ELIXIR MEDICAL
Elixir Medical is the only company with three CE Mark-approved drug-eluting systems spanning all market segments: the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold system, the DESyne® BD Novolimus Eluting Coronary Stent System (with biodegradable polymer), and the DESyne® Novolimus Eluting Coronary Stent System (with durable polymer).
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company’s next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.